Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Related ABT
#PreMarket Primer: Friday, December 19: U.S. Debates A Response To Sony Hackers
Analysts See No Sweeter Deal For Volcano
Making Money With Charles Payne: 10/17/14 (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Dec 2014JefferiesMaintainsBuy
Oct 2014Deutsche BankUpgradesHoldBuy
Jul 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional